ABCB1 and osteosarcoma: Furthermore, targeted disruption of ABCB1 using CRISPR/Cas9 has been shown to restore doxorubicin sensitivity in resistant osteosarcoma cell lines (e.g., KHOSR2, U-2OSR2), further confirming the role of CAFs-induced signaling in drug resistance (35).